Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
14.46
+0.96 (7.11%)
May 6, 2026, 12:59 PM EDT - Market open
Tonix Pharmaceuticals Holding Employees
Tonix Pharmaceuticals Holding had 142 employees as of December 31, 2025. The number of employees increased by 61 or 75.31% compared to the previous year.
Employees
142
Change (1Y)
61
Growth (1Y)
75.31%
Revenue / Employee
$92,303
Profits / Employee
-$873,387
Market Cap
205.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 142 | 61 | 75.31% |
| Dec 31, 2024 | 81 | -22 | -21.36% |
| Dec 31, 2023 | 103 | -14 | -11.97% |
| Dec 31, 2022 | 117 | 44 | 60.27% |
| Dec 31, 2021 | 73 | 47 | 180.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caribou Biosciences | 97 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| OnKure Therapeutics | 45 |
| Corbus Pharmaceuticals Holdings | 36 |
| Enlivex | 34 |
TNXP News
- 4 hours ago - Why Tonix Pharmaceuticals Shares Are Rallying Wednesday - Benzinga
- 6 hours ago - Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients - GlobeNewsWire
- 7 days ago - Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University - GlobeNewsWire
- 13 days ago - Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - GlobeNewsWire
- 6 weeks ago - Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - GlobeNewsWire